In a squeak­er, FDA Ad­Comm votes for an OK of Cem­pra’s an­tibi­ot­ic

Cem­pra $CEMP just bare­ly squeaked through an Ad­Comm re­view for its pro­posed new an­tibi­ot­ic solithromycin on Fri­day, with a slim ma­jor­i­ty of 7 to 6 cast­ing votes in its fa­vor on the key ques­tion of whether the ben­e­fits out­weighed the ob­vi­ous tox­i­c­i­ty risks as­so­ci­at­ed with their prod­uct.

Past safe­ty is­sues as­so­ci­at­ed with telithromycin (Ketek) clear­ly weighed on all the mem­bers, but with grow­ing re­sis­tance to ex­ist­ing an­tibi­otics be­com­ing an ever-grow­ing pub­lic health cri­sis, there were enough ‘yes’ votes to get this one over the line.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.